By Colin Kellaher

 

Amneal Pharmaceuticals Inc. (AMRX) Thursday said it received U.S. Food and Drug Administration approval for EluRyng, the first generic version of Merck & Co.'s (MRK) NuvaRing contraceptive.

The Bridgewater, N.J., pharmaceutical company said it has initiated commercialization activities for EluRyng, which it is manufacturing internally and launching Thursday.

NuvaRing had U.S. sales of about $976 million for the 12 months ended Oct. 31, Amneal said, citing healthcare data and analytics provider Iqvia.

Shares of Amneal, which closed Wednesday at $3.48, jumped nearly 17% in premarket trading Thursday.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 12, 2019 07:49 ET (12:49 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Merck Charts.